Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuationApichat Kaewdech, Teerha Piratvisuth, Yasuhito Tanaka et al.|Liver International|2020Cited by 46
Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE scorePimsiri Sripongpun, W. Ray Kim, Prowpanga Udompap et al.|JHEP Reports|2024Cited by 38
Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific regionPojsakorn Danpanichkul, Apichat Kaewdech, Karn Wijarnpreecha et al.|Scientific Reports|2024Cited by 35
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patientsYu Jun Wong, Juan G. Abraldeṣ, Vincent Chen et al.|Hepatology|2024Cited by 27
Diagnostic and prognostic performance of the <scp>SAFE</scp> score in non‐alcoholic fatty liver diseaseGuanlin Li, Terry Cheuk‐Fung Yip, Pimsiri Sripongpun et al.|Liver International|2023Cited by 26